Clinical trials: COVID-19 Vaccination
COVID-19
Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial
Since the emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen in late 2019, millions of people around the world have fallen ill and died from coronavirus disease 2019 (COVID-19), with…
- Trial name
- NCT05343871
- Testing
- Sinovac, AZD1222, BNT162b2
- Where
- 2 sites in Brazil, Pakistan
- Volunteers
- 2,354 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Safety, Immunogenicity, Vaccine
Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23
The main objective of this study was to evaluate the immunogenicity and safety of the booster dose of COVID-19 inactivated vaccine and co-immunization with quadrivalent influenza vaccine and 23-valent pneumonia polysaccharide…
- Conditions
- Safety, Immunogenicity, Vaccine, COVID-19 Vaccines, Influenza Vaccines
- Trial name
- QIV;PPV23 (NCT05298800)
- Testing
- Vaccine
- Where
- 3 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Covid19 Vaccination, Vaccine Uptake
Supporting Audit and Feedback to Encourage Vaccine Uptake
In Ontario, approximately 6,000 family physicians can access a secure online system that provides a report that lists the COVID-19 vaccination status for each patient in their roster.
- Trial name
- NCT05099497
- Testing
- Using Practice Facilitators to Support Physicians
- Where
- Canada
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Women's College Hospital
COVID-19, Influenza
Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine
This study is an open-label, single-center, randomized phase IV clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT04801888
- Testing
- Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28., Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14.
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
SARS-CoV-2 Infection, COVID-19
To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older
Results will be submitted, however please note that data are not yet available for all serology outcome measures. This will be a Phase 2/3, randomized, placebo-controlled, observer-blind study evaluating the safety, tolerability…
- Conditions
- SARS-CoV-2 Infection, COVID-19, Maternal Immunization
- Trial name
- NCT04754594
- Testing
- BNT162b2
- Where
- 90 sites in United States, Brazil and 3 more
- Volunteers
- 726 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
SARS-CoV-2
Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level After SARS-CoV-2 Vaccination (Trial 2)
Preliminarily explore the effect of oral probiotics in SARS-CoV-2 serum neutralizing antibody titer level and T cell response level (spot formation cell counting). Provide a reference for determining the appropriate oral regimen.
- Trial name
- NCT05195047
- Testing
- 1 week of probiotics(Week 1), 1 week of probiotics(Week 2)
- Where
- 2 sites in China
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Peking University
COVID-19
A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)
A total of 516 healthy subjects aged 18 years and above who have been vaccinated with 2 doses/3 doses of inactivated COVID-19 vaccine, will be enrolled, and randomly assigned to experimental group and control group in a 1:1…
- Trial name
- NCT05293548
- Testing
- Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09), Inactivated COVID-19 vaccine (Vero cells)
- Where
- United Arab Emirates
- Volunteers
- 516 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
SARS-CoV-2 Infection
Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above (6 Months After Two Doses)
To evaluate the immunogenicity and safety of the third dose SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in adults aged 18 years and above, who inoculated the third dose after 6 months since finished two doses schedule of…
- Trial name
- NCT05216484
- Testing
- SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
Covid19
Intravenous Immunoglobulins for the Treatment of Covid-19 Patients: a Clinical Trial
The current project is based on the immunological studies covering the potential of disease induced immunoglobulins as treatment regime.
- Trial name
- NCT04548557
- Testing
- intravenous immunoglobulin therapy
- Where
- Pakistan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Health Sciences Lahore
Covid19
Africa COVID-19 Vaccine Hesitancy
Vaccine hesitancy is defined by the WHO's Strategic Advisory Group of Experts on Immunization as a 'delay in acceptance or refusal of vaccination despite availability of vaccination services'.
- Trial name
- ACHES (NCT04912284)
- Where
- 5 sites in Burkina Faso, Guinea and 3 more
- Volunteers
- 4,977 people, healthy volunteers welcome
- Sponsor
- Bernhard Nocht Institute for Tropical Medicine
Immunogenicity, Efficacy
New Generation mRNA Booster Vaccine Against Emerging VOCs
Primary：Objectives ：SafetyTo describe the safetyprofile of all participants in each group up to 6months post-dose.Immunogenicity：To demonstrate the superiorityof neutralizing antibodyresponse in terms of geometric mean titers…
- Conditions
- Immunogenicity, Efficacy, Safety
- Trial name
- NCT05580159
- Testing
- SW-BIC-213, SARS-Cov-2 Vaccina(Vero Cell ) Inactivated
- Where
- Laos
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Stemirna Therapeutics
Autoimmune State, SARS-CoV-2 Infection
Security Efficacy COVID-19 Vaccination
Preliminary data support a possible molecular mimicry between SARS-CoV-2 and autologous components. This suggests the occurrence of autoimmunity during COVID-19. Consistently, autoimmunity may occur after SARS-CoV2 vaccination.
- Trial name
- SECVAX (NCT05743361)
- Testing
- Blood sampling
- Where
- Italy
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Istituto Auxologico Italiano
COVID-19 Infection, COVID-19 Vaccine
To Explore the Protective Effect of SARS-CoV-2 Vaccination on Cancer Patients Infected With SARS-CoV-2
For tumor patients, the virus antibody titer produced by the SARS-CoV-2 vaccine is often lower than that of normal people in a short period of time, but in the long run, it can significantly reduce the infection rate and fatality…
- Trial name
- NCT05774171
- Testing
- no intervention
- Where
- China
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Coronavirus
COVID-2019 Testing and Vaccination Among African American and Latinx Public Housing Residents
This proposal seeks to enhance acceptability and uptake of COVID-19 testing and vaccination to engage African American and Latinx public housing residents in South Los Angeles.
- Trial name
- NCT04542395
- Testing
- Increasing Willingness and Uptake of COVID-19 Testing and Vaccination
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Charles Drew University of Medicine and Science
CLL, Multiple Myeloma
The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19
The corona pandemic is a continuing global challenge due to Corona Virus 2019 (COVID-19). The purpose of the study is to evaluate the capability of Haemato-oncology patients to generate antibodies against COVID-19 after infection…
- Conditions
- CLL, Multiple Myeloma, Lymphoma
- Trial name
- NCT04746092
- Where
- Israel
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Chronic Kidney Disease 5D, Chronic Kidney Disease 5T
Humoral and Cellular İmmune Response to SARS-CoV-2 mRNA BNT162b2 Vaccine in Children With Chronic Kidney Diseases
Coronavirus 2019 (COVID-19) infection is associated with higher morbidity and mortality in adult patients on dialysis, and kidney transplant recipients (KTRs).
- Trial name
- NCT05465863
- Testing
- SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer-BioNTech®)
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
COVID-19
Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine
This is an open-label, randomized, parallel-controlled clinical trial to evaluate the safety and immunogenicity of heterologous prime-boost immunization with an aerosolized (Ad5-nCoV-IH) or intramuscular (Ad5-nCoV-IM) Ad5-nCoV…
- Trial name
- NCT05303584
- Testing
- Ad5-nCoV-IH, Ad5-nCoV-IM, CoronaVac
- Where
- China
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Vaccine Reaction
SARS-CoV-2 Antibodies and Virus Neutralisation in a Cohort Vaccinted Against COVID-19
Analysis of SARS-CoV-2 antibodies and serum virus neutralisation in vaccinated heath care personnel. Analysis of virus neutralisation as a function of age, gender, and history of COVID-19 infection.
- Trial name
- DER-CoV2-001 (NCT04979871)
- Testing
- Venous bleeding
- Where
- Switzerland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Zurich
COVID-19 Pandemic, SARS-CoV2 Infection
Hacettepe University COVID-19 Vaccinated's Health Cohort- Students of Health Sciences
The first COVID-19 case in Turkey was reported on March 11, 2000. National COVID-19 mass vaccination was initiated on Jan 13, 202, with two doses of CoronaVac (R) inactivated vaccine (of Sinovac), 28 days apart.
- Conditions
- COVID-19 Pandemic, SARS-CoV2 Infection, Immunization; Infection, Health
- Trial name
- HU-CoVaCS (NCT05104385)
- Testing
- Observational, prospective, follow-up of the recipients of CoronaVac (inactivated), Pfizer-Biontech (mRNA) vaccines
- Where
- Turkey (Türkiye)
- Volunteers
- 1,223 people, healthy volunteers welcome
- Sponsor
- Hacettepe University
Covid19
COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA
This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity the combination of hAd5-S-Fusion+N-ETSD (Suspension for injection) and…
- Trial name
- NCT04732468
- Testing
- hAd5-S-Fusion+N-ETSD (Suspension for injection), hAd5-SFusion+ N-ETSD (Oral capsule)
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.